838. ETX2514/sulbactam - Entasis Therapeutics
Session: Symposium: Exploring the Antibiotic Pipeline 2018
Thursday, October 4, 2018: 3:00 PM
Room: N Hall D
Robin Isaacs, MD, Entasis Therapeutics Inc, Waltham, MA

Robin Isaacs, M.D., has served as Chief Medical Officer of Entasis Therapeutics since July 2015. Prior to this, Dr. Isaacs worked at Merck Research Laboratory, a division of Merck & Co., Inc., from 1997 to 2015. Between 2009 and 2015, Dr. Isaacs served as a vice president and therapeutic area head, leading the vaccine and infectious disease clinical development groups in global clinical development. Prior to that, he was an associate professor of infectious disease at the University of Mississippi Medical Center in Jackson, Mississippi. Dr. Isaacs completed a clinical and research fellowship in infectious diseases at the University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Isaacs received his M.D. from the University of Auckland.


Disclosures:

R. Isaacs, Entasis Therapeutics: Employee , I own stock and/or stock options. and Salary .

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.